What is West Pharmaceutical Services's SG&A?

West Pharmaceutical Services (WST) reported SG&A of $99.5M in Q1 2026.

How has West Pharmaceutical Services's SG&A changed year-over-year?

West Pharmaceutical Services's SG&A increased by 13.1% year-over-year, from $88M to $99.5M.

What is the long-term trend for West Pharmaceutical Services's SG&A?

Over 4 years (2021 to 2025), West Pharmaceutical Services's SG&A has grown at a 2.1% compound annual growth rate (CAGR), from $362.8M to $393.6M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

West Pharmaceutical Services WST SG&A

SG&A at other companies

Becton, Dickinson and CompanyBDX

$1.21B+8.6%

Halozyme TherapeuticsHALO

$57.88M+36.6%

AVT

AvantorAVTR

$401.2M+3.5%

DowDOW

$417M+13.9%

DuPont de Nemours, Inc.DD

$255M+9.0%

Sonoco ProductsSON

$201.54M-3.6%

Segments

By segment

See full

Proprietary Products$65M+7.8%

West Vantage$7.8M—

Other financials

Income statement

See full

Revenue$844.9M+21.0%

Gross profit$296.4M+27.8%

Operating income$177.1M+65.5%

Net income$138.8M+54.6%

EPS (diluted)$1.92+56.1%

Balance sheet

See full

Cash & equivalents$521.4M+29.0%

Total debt$321.0M+4.4%

Total equity$3.0B+11.5%

Total assets$4.1B+13.6%

Cash flow

See full

Operating cash flow$89.9M-30.5%

CapEx$42.7M-40.1%

Free cash flow$47.2M-18.8%

Valuation

See full

Market cap$25.36B+64.2%

Enterprise value$25.16B+65.1%

P/E46.7×+15.1×

P/S7.9×+2.7×

Profitability

See full

Gross margin36.3%+1.7pp

Operating margin20.3%+1.2pp

Net margin16.8%+0.7pp

FCF margin14.2%+3.6pp

Returns & leverage

See full

Return on equity19.1%+1.7pp

Debt / equity0.1×0.0×

Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is West Pharmaceutical Services's SG&A?: West Pharmaceutical Services (WST) reported SG&A of $99.5M in Q1 2026.
How has West Pharmaceutical Services's SG&A changed year-over-year?: West Pharmaceutical Services's SG&A increased by 13.1% year-over-year, from $88M to $99.5M.
What is the long-term trend for West Pharmaceutical Services's SG&A?: Over 4 years (2021 to 2025), West Pharmaceutical Services's SG&A has grown at a 2.1% compound annual growth rate (CAGR), from $362.8M to $393.6M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.